Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.88 USD | +1.94% | +0.74% | +95.46% |
Jun. 03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
Jun. 03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 492M |
---|---|---|---|---|---|
Net income 2024 * | -66M | Net income 2025 * | -78M | EV / Sales 2024 * | - |
Net cash position 2024 * | 327M | Net cash position 2025 * | 501M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-9.53
x | P/E ratio 2025 * |
-10.3
x | Employees | 91 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.22% |
Latest transcript on Neurogene Inc.
1 day | +1.94% | ||
1 week | +0.74% | ||
Current month | +0.74% | ||
1 month | +11.61% | ||
3 months | -2.07% | ||
Current year | +95.46% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 37.88 | +1.94% | 22,570 |
24-06-06 | 37.16 | -0.83% | 65,948 |
24-06-05 | 37.47 | -0.69% | 48,886 |
24-06-04 | 37.73 | +1.34% | 45,987 |
24-06-03 | 37.23 | -0.98% | 62,937 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+95.46% | 492M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- NGNE Stock